DXCM delivered a Q2 earnings beat that flipped the script entirely — the defensive hedging that dominated the pre-print note has given way to a broad analyst upgrade cycle and the stock's strongest weekly move in months.
The price action tells the story first. DXCM closed Friday at $83.45, up nearly 12% on the day after the July 30 print and 16.6% on the week. That contrasts sharply with the cautious setup documented ahead of earnings, when put/call positioning was at its most defensive in nearly a year. The stock's 24% one-month gain means it has now recovered significant ground from the mid-$60s lows seen earlier in the year. Peers moved far less sharply: IDXX gained 2.7% on the week and PODD added 1.3%, while SYK actually fell 1.4%. DXCM's outperformance was decisive and stock-specific.
The options market confirms the shift in tone — but not entirely cleanly. The put/call ratio spiked to 1.19 on July 31, its 52-week high and more than four standard deviations above its 20-day average of 0.81. On its face that sounds defensive, but the context matters: this reading came the day after a large earnings gap-up, when traders aggressively buying puts to lock in gains or hedge a fast-moving position is common. The borrow market has remained entirely relaxed throughout. Availability is extremely loose at roughly 1,844% — shares available to borrow dwarf the short position by almost 20 to one. Borrowing cost has eased further, falling nearly 19% on the week to just 0.39%. Short interest is a modest 4.8% of the free float and has been drifting slightly lower over the week, down about 1.6%. There is no short-squeeze pressure here and no sign of a borrow squeeze forming.
The Street's reaction to the print was close to uniform bullishness. Ten analysts raised price targets on July 31 alone, all maintaining positive or neutral ratings. The bulls are firmly in control of the consensus — 22 buy ratings, with Mizuho, Piper Sandler, Stifel, and Truist all raising targets into the $93–$95 range. The notable holdout is JP Morgan, which raised its target from $65 to $82 while keeping a Neutral rating — a meaningful target lift that still trails the current price of $83.45, signalling the firm sees limited near-term upside even after the beat. The consensus mean target is $91.64, implying about 10% further upside from current levels. The bull case remains intact: CGM market expansion, 15-day sensor adoption, and a path to mid-teens revenue growth with 20%+ EPS growth through 2028. The bear flags — US market slowdown risk and competitive pressure in the T1 segment — have not disappeared, but the quarter appears to have pushed them further into the background for now.
Institutional positioning adds a constructive backdrop. BlackRock holds 10.3% of shares and added 647,000 shares in the most recent reporting period. Wellington Management built a meaningful new position, adding over six million shares. On the other side, insider activity has been consistently one-directional: Executive Chairman Kevin Sayer sold shares twice in July — roughly $2 million combined — alongside smaller sales from the CLO and CCO. The net insider position over 90 days shows net selling of around $8.3 million in value. These are low-significance trades by ORTEX scoring, most likely tied to scheduled plans, but the pattern of executive selling into the rally is worth noting.
With no next earnings event yet announced, the focus shifts to whether the post-print momentum holds — specifically, whether the 15-day sensor ramp and any commentary on CMS T2NIT coverage translate into upward revisions to forward estimates over the coming weeks.
See the live data behind this article on ORTEX.
Open DXCM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
